Reported Earnings • May 22
First quarter 2026 earnings released: EPS: €0.20 (vs €0.31 in 1Q 2025) First quarter 2026 results: EPS: €0.20 (down from €0.31 in 1Q 2025). Revenue: €54.1m (down 1.8% from 1Q 2025). Net income: €1.80m (down 35% from 1Q 2025). Profit margin: 3.3% (down from 5.0% in 1Q 2025). Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 23% per year whereas the company’s share price has fallen by 19% per year. Declared Dividend • May 20
Dividend of €0.29 announced Dividend of €0.29 is the same as last year. Ex-date: 25th June 2026 Payment date: 29th June 2026 Dividend yield will be 2.7%, which is lower than the industry average of 6.1%. Sustainability & Growth Dividend is covered by earnings (26% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 9.2% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 42% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Annonce • Jun 26
Nabaltec AG Resolves to Distribute A Dividend Nabaltec AG at the AGM held on 25 June 2025, resolved to distribute a dividend totaling EUR 2.55 million, which corresponds to a payout of EUR 0.29 per share (previous year: EUR 0.28 per share). The remaining distributable profit of EUR 60.0 million will be carried forward to new account and thus contribute to strengthening the company’s equity – an important step in further implementing the company’s growth strategy. Annonce • May 23
Nabaltec Ag Affirms Earnings Guidance for 2025 Nabaltec AG affirmed earnings guidance for 2025. For the period, the company expects Revenue growth in a range of 3% to 5%; EBIT margin in a range of 7% to 9%. Annonce • May 13
Nabaltec AG, Annual General Meeting, Jun 25, 2025 Nabaltec AG, Annual General Meeting, Jun 25, 2025, at 10:00 W. Europe Standard Time. Annonce • May 07
Nabaltec AG announces Annual dividend, payable on June 30, 2025 Nabaltec AG announced Annual dividend of EUR 0.2900 per share payable on June 30, 2025, ex-date on June 26, 2025 and record date on June 27, 2025. New Risk • Aug 25
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 3.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 3.0% per year for the foreseeable future. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (6.6% net profit margin). Reported Earnings • Aug 25
Second quarter 2024 earnings released: EPS: €0.46 (vs €0.27 in 2Q 2023) Second quarter 2024 results: EPS: €0.46 (up from €0.27 in 2Q 2023). Revenue: €55.2m (up 12% from 2Q 2023). Net income: €4.07m (up 69% from 2Q 2023). Profit margin: 7.4% (up from 4.9% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Upcoming Dividend • Jun 19
Upcoming dividend of €0.28 per share Eligible shareholders must have bought the stock before 26 June 2024. Payment date: 28 June 2024. Payout ratio is a comfortable 21% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (5.2%). Reported Earnings • May 26
First quarter 2024 earnings released: EPS: €0.39 (vs €0.35 in 1Q 2023) First quarter 2024 results: EPS: €0.39 (up from €0.35 in 1Q 2023). Revenue: €55.0m (down 3.8% from 1Q 2023). Net income: €3.40m (up 9.7% from 1Q 2023). Profit margin: 6.2% (up from 5.4% in 1Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. Declared Dividend • May 13
Dividend of €0.28 announced Shareholders will receive a dividend of €0.28. Ex-date: 26th June 2024 Payment date: 28th June 2024 Dividend yield will be 1.9%, which is lower than the industry average of 6.1%. Sustainability & Growth Dividend is covered by earnings (22% earnings payout ratio) but not covered by cash flows (102% cash payout ratio). The dividend has increased by an average of 17% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 47% over the next 2 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Apr 26
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2023 results: EPS: €1.30 (down from €3.00 in FY 2022). Revenue: €203.3m (down 7.4% from FY 2022). Net income: €11.4m (down 57% from FY 2022). Profit margin: 5.6% (down from 12% in FY 2022). Revenue missed analyst estimates by 3.1%. Earnings per share (EPS) exceeded analyst estimates by 14%. Revenue is forecast to grow 4.5% p.a. on average during the next 2 years, compared to a 3.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Buy Or Sell Opportunity • Jan 26
Now 20% undervalued Over the last 90 days, the stock has risen 18% to €17.10. The fair value is estimated to be €21.48, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 79%. Revenue is forecast to grow by 5.4% in 2 years. Earnings are forecast to grow by 32% in the next 2 years. Valuation Update With 7 Day Price Move • Jan 22
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €17.90, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 13x in the Chemicals industry in Germany. Total loss to shareholders of 22% over the past three years. Buying Opportunity • Jan 10
Now 20% undervalued Over the last 90 days, the stock is up 14%. The fair value is estimated to be €21.49, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 79%. Revenue is forecast to grow by 5.4% in 2 years. Earnings is forecast to grow by 32% in the next 2 years. Valuation Update With 7 Day Price Move • Dec 22
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €18.65, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 16x in the Chemicals industry in Germany. Total loss to shareholders of 30% over the past three years. Buying Opportunity • Nov 25
Now 24% undervalued after recent price drop Over the last 90 days, the stock is down 16%. The fair value is estimated to be €19.83, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 79%. Revenue is forecast to grow by 5.4% in 2 years. Earnings is forecast to grow by 32% in the next 2 years. Reported Earnings • Nov 23
Third quarter 2023 earnings released: EPS: €0.33 (vs €1.38 in 3Q 2022) Third quarter 2023 results: EPS: €0.33 (down from €1.38 in 3Q 2022). Revenue: €51.1m (down 9.9% from 3Q 2022). Net income: €2.92m (down 76% from 3Q 2022). Profit margin: 5.7% (down from 22% in 3Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. New Risk • Nov 23
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 6.0% Last year net profit margin: 13% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (6.0% net profit margin). New Risk • Oct 16
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 2.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 2.4% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Buying Opportunity • Sep 08
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 18%. The fair value is estimated to be €21.96, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 82%. Revenue is forecast to grow by 7.8% in 2 years. Earnings is forecast to decline by 13% in the next 2 years. Reported Earnings • Aug 27
Second quarter 2023 earnings released: EPS: €0.27 (vs €0.64 in 2Q 2022) Second quarter 2023 results: EPS: €0.27 (down from €0.64 in 2Q 2022). Revenue: €49.2m (down 12% from 2Q 2022). Net income: €2.41m (down 57% from 2Q 2022). Profit margin: 4.9% (down from 10.0% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 82% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. New Risk • Aug 18
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.5% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 5.2% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Annonce • Jun 29
Nabaltec AG Approves Dividend Nabaltec AG announced that at its AGM held on June 28, 2023, the shareholders approved distribute a dividend totaling EUR 2.46 million. This corresponds to EUR 0.28 per share. The remaining distributable profit of EUR 41.1 million will be carried forward to new account and thus left in the company to further strengthen liquidity. Upcoming Dividend • Jun 22
Upcoming dividend of €0.28 per share at 1.4% yield Eligible shareholders must have bought the stock before 29 June 2023. Payment date: 03 July 2023. Payout ratio is a comfortable 9.9% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (6.3%). Annonce • May 26
Nabaltec AG Provides Earnings Guidance for the Full Year 2023 Nabaltec AG provided earnings guidance for the full year 2023. For the period, the company expects revenue growth of 3% to 5% and EBIT margin of 8% to 10%. Reported Earnings • May 03
Full year 2022 earnings: EPS exceeds analyst expectations Full year 2022 results: EPS: €3.00 (up from €1.85 in FY 2021). Revenue: €222.8m (up 19% from FY 2021). Net income: €26.4m (up 62% from FY 2021). Profit margin: 12% (up from 8.7% in FY 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 9.1%. Revenue is expected to decline by 2.5% p.a. on average during the next 2 years, while revenues in the Chemicals industry in Germany are expected to grow by 2.6%. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Price Target Changed • Mar 28
Price target decreased by 10% to €31.00 Down from €34.50, the current price target is provided by 1 analyst. New target price is 35% above last closing price of €22.90. Stock is down 28% over the past year. The company is forecast to post earnings per share of €2.75 for next year compared to €1.85 last year. Price Target Changed • Nov 29
Price target increased to €34.50 Up from €31.50, the current price target is an average from 2 analysts. New target price is 45% above last closing price of €23.80. Stock is down 33% over the past year. The company is forecast to post earnings per share of €2.75 for next year compared to €1.85 last year. Reported Earnings • Nov 27
Third quarter 2022 earnings released: EPS: €1.38 (vs €0.49 in 3Q 2021) Third quarter 2022 results: EPS: €1.38 (up from €0.49 in 3Q 2021). Revenue: €56.6m (up 21% from 3Q 2021). Net income: €12.1m (up 183% from 3Q 2021). Profit margin: 22% (up from 9.2% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to stay flat during the next 3 years, in line with the revenue forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Price Target Changed • Nov 16
Price target decreased to €31.50 Down from €36.00, the current price target is an average from 2 analysts. New target price is 53% above last closing price of €20.60. Stock is down 44% over the past year. The company is forecast to post earnings per share of €1.85 for next year compared to €1.85 last year. Price Target Changed • Oct 20
Price target decreased to €31.50 Down from €36.00, the current price target is an average from 2 analysts. New target price is 54% above last closing price of €20.50. Stock is down 36% over the past year. The company is forecast to post earnings per share of €2.03 for next year compared to €1.85 last year. Reported Earnings • Aug 26
Second quarter 2022 earnings released: EPS: €0.64 (vs €0.49 in 2Q 2021) Second quarter 2022 results: EPS: €0.64 (up from €0.49 in 2Q 2021). Revenue: €57.3m (up 19% from 2Q 2021). Net income: €5.60m (up 29% from 2Q 2021). Profit margin: 9.8% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 9.0%, compared to a 2.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 6% per year. Valuation Update With 7 Day Price Move • Jul 23
Investor sentiment improved over the past week After last week's 17% share price gain to €26.90, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 8x in the Chemicals industry in Germany. Total loss to shareholders of 18% over the past three years. Upcoming Dividend • Jun 23
Upcoming dividend of €0.25 per share Eligible shareholders must have bought the stock before 30 June 2022. Payment date: 04 July 2022. Trailing yield: 0.9%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (5.7%). Reported Earnings • Jun 04
First quarter 2022 earnings: EPS and revenues exceed analyst expectations First quarter 2022 results: EPS: €0.53 (up from €0.27 in 1Q 2021). Revenue: €55.0m (up 19% from 1Q 2021). Net income: €4.67m (up 96% from 1Q 2021). Profit margin: 8.5% (up from 5.2% in 1Q 2021). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) also surpassed analyst estimates by 8.8%. Over the next year, revenue is forecast to grow 14%, compared to a 6.2% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Price Target Changed • May 24
Price target decreased to €37.50 Down from €41.00, the current price target is an average from 2 analysts. New target price is 37% above last closing price of €27.40. Stock is down 21% over the past year. The company is forecast to post earnings per share of €1.92 for next year compared to €1.85 last year. Reported Earnings • Apr 30
Full year 2021 earnings: EPS and revenues exceed analyst expectations Full year 2021 results: €1.85 loss per share (up from €2.23 loss in FY 2020). Revenue: €190.2m (up 19% from FY 2020). Net income: €16.3m (up €35.9m from FY 2020). Profit margin: 8.5% (up from net loss in FY 2020). The move to profitability was primarily driven by higher revenue. Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to grow 13%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 99 percentage points per year, which is a significant difference in performance. Reported Earnings • Nov 27
Third quarter 2021 earnings: EPS exceeds analyst expectations Third quarter 2021 results: EPS: €0.49 (up from €0.15 in 3Q 2020). Revenue: €47.4m (up 28% from 3Q 2020). Net income: €4.30m (up 217% from 3Q 2020). Profit margin: 9.1% (up from 3.6% in 3Q 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) exceeded analyst estimates. Earnings per share (EPS) surpassed analyst estimates. Over the next year, revenue is forecast to grow 11%, compared to a 4.4% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 113 percentage points per year, which is a significant difference in performance. Price Target Changed • Oct 29
Price target increased to €40.50 Up from €37.00, the current price target is an average from 3 analysts. New target price is 23% above last closing price of €33.00. Stock is up 66% over the past year. The company is forecast to post earnings per share of €1.50 next year compared to a net loss per share of €2.23 last year. Reported Earnings • Aug 27
Second quarter 2021 earnings released: EPS €0.49 (vs €0.12 loss in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €48.5m (up 33% from 2Q 2020). Net income: €4.35m (up €5.40m from 2Q 2020). Profit margin: 9.0% (up from net loss in 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 100 percentage points per year, which is a significant difference in performance. Reported Earnings • May 28
First quarter 2021 earnings released: EPS €0.27 (vs €0.14 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: €46.1m (up 1.3% from 1Q 2020). Net income: €2.38m (up 98% from 1Q 2020). Profit margin: 5.2% (up from 2.6% in 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 94 percentage points per year, which is a significant difference in performance. Price Target Changed • May 15
Price target increased to €37.00 Up from €31.50, the current price target is an average from 2 analysts. New target price is 15% above last closing price of €32.20. Stock is up 56% over the past year. Reported Earnings • May 02
Full year 2020 earnings released: €2.23 loss per share (vs €1.22 profit in FY 2019) The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: €162.5m (down 9.6% from FY 2019). Net loss: €19.7m (down 284% from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Price Target Changed • Apr 30
Price target increased to €33.50 Up from €30.50, the current price target is an average from 2 analysts. New target price is 6.0% above last closing price of €31.60. Stock is up 41% over the past year. Is New 90 Day High Low • Feb 27
New 90-day high: €29.80 The company is up 15% from its price of €25.90 on 27 November 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €28.95 per share. Is New 90 Day High Low • Nov 11
New 90-day high: €23.00 The company is up 21% from its price of €19.00 on 13 August 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €62.62 per share. Is New 90 Day High Low • Oct 11
New 90-day high: €21.00 The company is up 2.0% from its price of €20.60 on 13 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €60.09 per share.